Literature DB >> 7545093

Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells.

E Robinson1, E C Keystone, T J Schall, N Gillett, E N Fish.   

Abstract

Earlier studies from this laboratory provided evidence for restricted cytokine expression in the T cell population in RA tissues. Specifically, IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) gene expression levels were low. The selective chemoattractant and activation effects of chemokines on leucocytes identify them as potentially ideal candidates in mediating selective inflammatory processes in RA. Accordingly, we undertook studies to examine constitutive chemokine gene expression in RA tissues. RANTES, monocyte chemotactic protein-1 (MCP-1) and MIP-1 beta gene expression was examined in both the T and non-T cell populations in RA peripheral blood (PB), synovial fluid (SF) and synovial tissues (ST). Our results identified elevated levels of both RANTES and MIP-1 beta gene expression in circulating RA PB and SF T cells. By contrast, MCP-1 expression was virtually absent in RA PB, yet elevated MCP-1 mRNA levels were detected primarily in the non-T cell populations of the SF and ST samples. Histological examination of affected rheumatoid joints revealed extensive RANTES and MIP-1 beta expression in sites of lymphocyte infiltration and cell proliferation, namely the synovial lining and sublining layers. Fractionation or RA ST patient samples revealed that RANTES expression was restricted to the T cells, whereas MIP-1 beta expression was detected in both T and non-T fractions. These data suggest that MCP-1, MIP-1 beta and RANTES may have a central role in the trafficking of reactive molecules involved in immunoregulation and in the inflammatory processes in RA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545093      PMCID: PMC1553247          DOI: 10.1111/j.1365-2249.1995.tb03126.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.

Authors:  E M Lemmel; M Franke; W Gaus; P W Hartl; P H Hofschneider; K Miehlke; K Machalke; H J Obert
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

2.  A human T cell-specific molecule is a member of a new gene family.

Authors:  T J Schall; J Jongstra; B J Dyer; J Jorgensen; C Clayberger; M M Davis; A M Krensky
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

3.  Increased helper inducer and decreased suppressor inducer phenotypes in the rheumatoid joint.

Authors:  H P Lasky; K Bauer; R M Pope
Journal:  Arthritis Rheum       Date:  1988-01

4.  Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis.

Authors:  J J Cush; P E Lipsky
Journal:  Arthritis Rheum       Date:  1988-10

5.  la-positive T lymphocytes are the producer cells of interferon gamma.

Authors:  I Schober; R Braun; H Reiser; K Munk; M Leroux; H Kirchner
Journal:  Exp Cell Res       Date:  1984-06       Impact factor: 3.905

6.  Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis.

Authors:  P Emery; K C Gentry; I R Mackay; K D Muirden; M Rowley
Journal:  Arthritis Rheum       Date:  1987-08

7.  Interferons in rheumatoid arthritis: alterations in production and response related to disease activity.

Authors:  P J Hertzog; P Emery; B F Cheetham; I R Mackay; A W Linnane
Journal:  Clin Immunol Immunopathol       Date:  1988-08

8.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

9.  Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta.

Authors:  A E Postlethwaite; R Raghow; G P Stricklin; H Poppleton; J M Seyer; A H Kang
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

10.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  52 in total

1.  Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration.

Authors:  N J Borthwick; A N Akbar; L P MacCormac; M Lowdell; J L Craigen; I Hassan; J E Grundy; M Salmon; K L Yong
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Cathepsin G: the significance in rheumatoid arthritis as a monocyte chemoattractant.

Authors:  Junya Miyata; Kenji Tani; Keiko Sato; Shinsaku Otsuka; Tomoyuki Urata; Battur Lkhagvaa; Chiyuki Furukawa; Nobuya Sano; Saburo Sone
Journal:  Rheumatol Int       Date:  2006-09-15       Impact factor: 2.631

3.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

Review 4.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Chemokines in rheumatoid arthritis.

Authors:  Z Szekanecz; R M Strieter; S L Kunkel; A E Koch
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

8.  Close resemblance between chemokine receptor expression profiles of lymphoproliferative disease of granular lymphocytes and their normal counterparts in association with elevated serum concentrations of IP-10 and MIG.

Authors:  Kayoko Momose; Hideki Makishima; Toshiro Ito; Hideyuki Nakazawa; Shigetaka Shimodaira; Kendo Kiyosawa; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

9.  The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis.

Authors:  Piotr Adrian Klimiuk; Jacek Kita; Justyna Chwiecko; Stanislaw Sierakowski
Journal:  Clin Rheumatol       Date:  2008-07-29       Impact factor: 2.980

10.  Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.

Authors:  J J Haringman; M C Kraan; T J M Smeets; K H Zwinderman; P P Tak
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.